| Ident. | Authors (with country if any) | Title |
|---|
| 000010 |
Jan Felix Drexler [Allemagne] ; Victor Max Corman [Allemagne] ; Christian Drosten [Allemagne] | Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS |
| 000019 |
Graham Simmons [États-Unis] ; Pawel Zmora [Allemagne] ; Stefanie Gierer [Allemagne] ; Adeline Heurich [Allemagne] ; Stefan Pöhlmann [Allemagne] | Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research |
| 000022 |
Rolf Hilgenfeld [Allemagne] ; Malik Peiris [Hong Kong] | From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses |
| 000032 |
Li-Jun Wang [République populaire de Chine] ; Chang-An Geng [République populaire de Chine] ; Yun-Bao Ma [République populaire de Chine] ; Xiao-Yan Huang [République populaire de Chine] ; JIE LUO [République populaire de Chine] ; HAO CHEN [République populaire de Chine] ; Rui-Hua Guo [République populaire de Chine] ; Xue-Mei Zhang [République populaire de Chine] ; Ji-Jun Chen [République populaire de Chine] | Synthesis, structure-activity relationships and biological evaluation of caudatin derivatives as novel anti-hepatitis B virus agents |
| 000033 |
Li-Jun Wang [République populaire de Chine] ; Chang-An Geng [République populaire de Chine] ; Yun-Bao Ma [République populaire de Chine] ; Xiao-Yan Huang [République populaire de Chine] ; JIE LUO [République populaire de Chine] ; HAO CHEN [République populaire de Chine] ; Xue-Mei Zhang [République populaire de Chine] ; Ji-Jun Chen [République populaire de Chine] | Synthesis, biological evaluation and structure-activity relationships of glycyrrhetinic acid derivatives as novel anti-hepatitis B virus agents |
| 000062 |
ZIWEN WANG [République populaire de Chine] ; LEI WANG [République populaire de Chine] ; SHUANG MA [République populaire de Chine] ; YUXIU LIU [République populaire de Chine] ; LIZHONG WANG [République populaire de Chine] ; QINGMIN WANG [République populaire de Chine] | Design, Synthesis, Antiviral Activity, and SARs of 14-Aminophenanthroindolizidines |
| 000072 |
Thi Thanh Hanh Nguyen [Corée du Sud] ; Hwa-Ja Ryu [Corée du Sud] ; Se-Hoon Lee [Corée du Sud] ; Soonwook Hwang [Corée du Sud] ; Vincent Breton [France] ; JOON HAENG RHEE [Corée du Sud] ; Doman Kim [Corée du Sud] | Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation |
| 000078 |
Rui-Hua Guo [République populaire de Chine] ; QUAN ZHANG [République populaire de Chine] ; Yun-Bao Ma [République populaire de Chine] ; JIE LUO [République populaire de Chine] ; Chang-An Geng [République populaire de Chine] ; Li-Jun Wang [République populaire de Chine] ; Xue-Mei Zhang [République populaire de Chine] ; JUN ZHOU [République populaire de Chine] ; Zhi-Yong Jiang [République populaire de Chine] ; Ji-Jun Chen [République populaire de Chine] | Structure-activity relationships study of 6-chloro-4-(2-chlorophenyl)-3-(2-hydroxyethyl) quinolin-2(1H)-one derivatives as novel non-nucleoside anti-hepatitis B virus agents |
| 000114 |
MI KYOUNG KIM [Corée du Sud] ; Mi-Sun Yu [Corée du Sud] ; HYE RI PARKA [Corée du Sud] ; KYUNG BO KIM [Corée du Sud] ; Chaewoon Lee [Corée du Sud] ; SUH YOUNG CHO [Corée du Sud] ; Jihoon Kang [Corée du Sud] ; Hyunjun Yoon [Corée du Sud] ; Dong-Eun Kim [Corée du Sud] ; Hyunah Choo [Corée du Sud] ; Yong-Joo Jeong [Corée du Sud] ; Youhoon Chong [Corée du Sud] | 2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV) |
| 000118 |
Larry J. Anderson [États-Unis] ; SUXIANG TONG [États-Unis] | Update on SARS research and other possibly zoonotic coronaviruses |
| 000127 |
R. Ramajayam [Taïwan] ; Kian-Pin Tan [Taïwan] ; Hun-Ge Liu [Taïwan] ; Po-Huang Liang [Taïwan] | Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease |
| 000128 |
Iou-Jiun Kang [Taïwan] ; Li-Wen Wang [Taïwan] ; Teng-Kuang Yeh [Taïwan] ; Chung-Chi Lee [Taïwan] ; Yen-Chun Lee [Taïwan] ; Sheng-Ju Hsu [Taïwan] ; Yen-Shian Wu [Taïwan] ; Jing-Chyi Wang [Taïwan] ; Yu-Sheng Chao [Taïwan] ; Andrew Yueh [Taïwan] ; Jyh-Haur Chern [Taïwan] | Synthesis, activity, and pharmacokinetic properties of a series of conformationally-restricted thiourea analogs as novel hepatitis C virus inhibitors |
| 000129 |
R. Ramajayam [Taïwan] ; Kian-Pin Tan [Taïwan] ; Hun-Ge Liu [Taïwan] ; Po-Huang Liang [Taïwan] | Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors |
| 000143 |
Cheng-Wei Yang [Taïwan] ; Yue-Zhi Lee [Taïwan] ; Iou-Jiun Kang [Taïwan] ; Dale L. Bamard [États-Unis] ; Jia-Tsrong Jan [Taïwan] ; DU LIN [Taïwan] ; Chun-Wei Huang [Taïwan] ; Teng-Kuang Yeh [Taïwan] ; Yu-Sheng Chao [Taïwan] ; Shiow-Ju Lee [Taïwan] | Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus |
| 000159 |
YOUNG BAE RYU [Corée du Sud] ; HYUNG JAE JEONG [Corée du Sud] ; JANG HOON KIM [Corée du Sud] ; YOUNG MIN KIM [Corée du Sud] ; Ji-Young Park [Corée du Sud] ; Doman Kim [Corée du Sud] ; Thi Thanh Hanh Naguyen [Corée du Sud] ; Su-Jin Park [Corée du Sud] ; JONG SUN CHANG [Corée du Sud] ; KI HUN PARK [Corée du Sud] ; Mun-Chual Rho [Corée du Sud] ; WOO SONG LEE [Corée du Sud] | Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition |
| 000177 |
Christopher Mcguigan [Royaume-Uni] ; Mary Rose Kelleher [Royaume-Uni] ; Plinio Perrone [Royaume-Uni] ; Sinead Mulready [Royaume-Uni] ; Giovanna Luoni [Royaume-Uni] ; Felice Daverio [Royaume-Uni] ; Sonal Rajyaguru [États-Unis] ; Sophie Le Pogam [États-Unis] ; Isabel Najera [États-Unis] ; Joseph A. Martin [États-Unis] ; Klaus Klumpp [États-Unis] ; David B. Smith [États-Unis] | The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4'-azidocytidine (R1479) |
| 000183 |
Arun K. Ghosh [États-Unis] ; Jun Takayama [États-Unis] ; Yoann Aubin [États-Unis] ; Kiira Ratia [États-Unis] ; Rima Chaudhuri [États-Unis] ; Yahira Baez [États-Unis] ; Katrina Sleeman [États-Unis] ; Melissa Coughlin [États-Unis] ; Daniel B. Nichols [États-Unis] ; Debbie C. Mulhearn [États-Unis] ; Bellur S. Prabhakar [États-Unis] ; Susan C. Bakery [États-Unis] ; Michael E. Johnson [États-Unis] ; Andrew D. Mesecar [États-Unis] | Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease |
| 000190 |
Tomoki Yoshikawa [États-Unis] ; Terence Hill [États-Unis] ; KUI LI [États-Unis] ; Clarence J. Peters [États-Unis] ; Chien-Te K. Tseng [États-Unis] | Severe Acute Respiratory Syndrome (SARS) Coronavirus-Induced Lung Epithelial Cytokines Exacerbate SARS Pathogenesis by Modulating Intrinsic Functions of Monocyte-Derived Macrophages and Dendritic Cells |
| 000198 |
Andrea Spallarossa [Italie] ; Sara Cesarini [Italie] ; Angelo Ranise [Italie] ; Silvia Schenone [Italie] ; Olga Bruno [Italie] ; Alberto Borassi [Italie] ; Paolo La Colla [Italie] ; Margherita Pezzullo [Italie] ; Giuseppina Sanna [Italie] ; Gabriella Collu [Italie] ; Barbara Secci [Italie] ; Roberta Loddo [Italie] | Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors |
| 000200 |
Andrea Spallarossa [Italie] ; Sara Cesarini [Italie] ; Angelo Ranise [Italie] ; Olga Bruno [Italie] ; Silvia Schenone [Italie] ; Paolo La Colla [Italie] ; Gabriella Collu [Italie] ; Giuseppina Sanna [Italie] ; Barbara Secci [Italie] ; Roberta Loddo [Italie] | Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors |
| 000221 |
Iou-Jiun Kang [Taïwan] ; Li-Wen Wang [Taïwan] ; Sheng-Ju Hsu [Taïwan] ; Chung-Chi Lee [Taïwan] ; Yen-Chun Lee [Taïwan] ; Yen-Shian Wu [Taïwan] ; Andrew Yueh [Taïwan] ; Jing-Chyi Wang [Taïwan] ; Tsu-An Hsu [Taïwan] ; Yu-Sheng Chao [Taïwan] ; Jyh-Haur Chern [Taïwan] | Design and efficient synthesis of novel arylthiourea derivatives as potent hepatitis C virus inhibitors |
| 000237 |
Sara Cesarini [Italie] ; Andrea Spallarossa [Italie] ; Angelo Ranise [Italie] ; Olga Bruno [Italie] ; Paolo La Colla [Italie] ; Barbara Secci [Italie] ; Gabriella Collu [Italie] ; Roberta Loddo [Italie] | Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2. Parallel synthesis, molecular modelling and structure-activity relationship studies on analogues of O-(2-phenylethyl)-N-phenylthiocarbamate |
| 000238 |
Sara Cesarini [Italie] ; Andrea Spallarossa [Italie] ; Angelo Ranise [Italie] ; Paola Fossa [Italie] ; Paolo La Colla [Italie] ; Giuseppina Sanna [Italie] ; Gabriella Collu [Italie] ; Roberta Loddo [Italie] | Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 1. Parallel synthesis, molecular modelling and structure-activity relationship studies on 0-[2-(hetero)arylethyl]-N-phenylthiocarbamates |
| 000240 |
Samson S. Y. Wong [Hong Kong] ; Kwok-Yung Yuen [Hong Kong] | The management of coronavirus infections with particular reference to SARS |
| 000246 |
Prasenjit Mukherjee [États-Unis] ; Prashant Desai [États-Unis] ; Larry Ross [États-Unis] ; E. Lucile White [États-Unis] ; Mitchell A. Avery [États-Unis] | Structure-based virtual screening against SARS-3CLpro to identify novel non-peptidic hits |
| 000267 |
CHUNYING NIU [Canada] ; JIANG YIN [Canada] ; JIANMIN ZHANG [Canada] ; John C. Vederas [Canada] ; Michael N. G. James [Canada] | Molecular docking identifies the binding of 3-chloropyridine moieties specifically to the S1 pocket of SARS-CoV Mpro |
| 000271 |
Dale L. Barnard [États-Unis] ; Craig W. Day [États-Unis] ; Kevin Bailey [États-Unis] ; Matthew Heiner [États-Unis] ; Robert Montgomery [États-Unis] ; Larry Lauridsen [États-Unis] ; Kie-Hoon Jung [États-Unis] ; Joseph K.-K. Li [États-Unis] ; Paul K. S. Chan [Hong Kong] ; Robert W. Sidwell [États-Unis] | Is the anti-psychotic, 10-(3-(dimethylamino)propyl)phenothiazine (promazine), a potential drug with which to treat SARS infections? Lack of efficacy of promazine on SARS-CoV replication in a mouse model |
| 000272 |
Bruno Canard [France] ; Jeremiah S. Joseph [États-Unis] ; Peter Kuhn [États-Unis] | International research networks in viral structural proteomics : Again, lessons from SARS |
| 000280 |
Carly Huitema [Canada] ; JIANMIN ZHANG [Canada] ; JIANG YIN [Canada] ; Michael N. G. James [Canada] ; John C. Vederas [Canada] ; Lindsay D. Eltis [Canada] | Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase : Evaluation of mode of action |
| 000291 |
Arun K. Ghosh [États-Unis] ; GANGLI GONG [États-Unis] ; Valerie Grum-Tokars [États-Unis] ; Debbie C. Mulhearn [États-Unis] ; Susan C. Baker [États-Unis] ; Melissa Coughlin [États-Unis] ; Bellur S. Prabhakar [États-Unis] ; Katrina Sleeman [États-Unis] ; Michael E. Johnson [États-Unis] ; Andrew D. Mesecar [États-Unis] | Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors |
| 000295 |
TAO MA [République populaire de Chine] ; LI LIU [Hong Kong] ; HAI XUE [République populaire de Chine] ; LI LI [République populaire de Chine] ; CHUNYAN HAN [République populaire de Chine] ; LIN WANG [République populaire de Chine] ; ZHIWEI CHEN [Hong Kong] ; GANG LIU [République populaire de Chine] | Chemical Library and Structure-Activity Relationships of 11-Demethyl-12-oxo Calanolide A Analogues as Anti-HIV-1 Agents |
| 000298 |
Cristina Fiore [Italie] ; Michael Eisenhut [Royaume-Uni] ; Rea Krausse [Allemagne] ; Eugenio Ragazzi [Italie] ; Donatella Pellati [Italie] ; Decio Armanini [Italie] ; Jens Bielenberg [Allemagne] | Antiviral Effects of Glycyrrhiza species |
| 000329 |
Masahiro Ikejiri [Japon] ; Masayuki Saijo [Japon] ; Shigeru Morikawa [Japon] ; Shuetsu Fukushi [Japon] ; Tetsuya Mizutani [Japon] ; Ichiro Kurane [Japon] ; Tokumi Maruyama [Japon] | Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents |
| 000330 |
Arun K. Ghosh [États-Unis] ; KAI XI [États-Unis] ; Valerie Grum-Tokars [États-Unis] ; XIAOMING XU [États-Unis] ; Kiira Ratia [États-Unis] ; WENTAO FU [États-Unis] ; Katherine V. Houser [États-Unis] ; Susan C. Baker [États-Unis] ; Michael E. Johnson [États-Unis] ; Andrew D. Mesecar [États-Unis] | Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors |
| 000331 |
Chih-Chun Wen [Taïwan] ; Yueh-Hsiung Kuo [Taïwan] ; Jia-Tsrong Jan [Taïwan] ; Po-Huang Liang [Taïwan] ; Sheng-Yang Wang [Taïwan] ; Hong-Gi Liu [Taïwan] ; Ching-Kuo Lee [Taïwan] ; Shang-Tzen Chang [Taïwan] ; Chih-Jung Kuo [Taïwan] ; Shoei-Sheng Lee [Taïwan] ; Chia-Chung Hou [Taïwan] ; Pei-Wen Hsiao [Taïwan] ; Shih-Chang Chien [Taïwan] ; Lie-Fen Shyur [Taïwan] ; Ning-Sun Yang [Taïwan] | Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus |
| 000355 |
Els Keyaerts [Belgique] ; Leen Vijgen [Belgique] ; Christophe Pannecouque [Belgique] ; Els Van Damme [Belgique] ; Willy Peumans [Belgique] ; Herman Egberink [Pays-Bas] ; Jan Balzarini [Belgique] ; Marc Van Ranst [Belgique] | Plant lectins are potent inhibitors of coronaviruses by interfering with two targets in the viral replication cycle |
| 000390 |
JIANMIN ZHANG [Canada] ; Hanna I. Pettersson [Canada] ; Carly Huitema [Canada] ; CHUNYING NIU [Canada] ; JIANG YIN [Canada] ; Michael N. G. James [Canada] ; Lindsay D. Eltis [Canada] ; John C. Vederas [Canada] | Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters |
| 000405 |
Masahiro Ikejiri [Japon] ; Takayuki Ohshima [Japon] ; Keizo Kato [Japon] ; Masaaki Toyama [Japon] ; Takayuki Murata [Japon] ; Kunitada Shimotohno [Japon] ; Tokumi Maruyama [Japon] | 5'-O-Masked 2'-deoxyadenosine analogues as lead compounds for hepatitis C virus (HCV) therapeutic agents |
| 000424 |
Syaulan Yang [Taïwan] ; Shu-Jen Chen [Taïwan] ; Min-Feng Hsu [Taïwan] ; Jen-Dar Wu [Taïwan] ; Chien-Te K. Tseng [États-Unis] ; Yu-Fan Liu [Taïwan] ; Hua-Chien Chen [Taïwan] ; Chun-Wei Kuo [Taïwan] ; Chi-Shen Wu [Taïwan] ; Li-Wen Chang [Taïwan] ; Wen-Chang Chen [Taïwan] ; Shao-Ying Liao [Taïwan] ; Teng-Yuan Chang [Taïwan] ; Hsin-Hui Hung [Taïwan] ; Hui-Lin Shr [Taïwan] ; Cheng-Yuan Liu [Taïwan] ; Yu-An Huang [Taïwan] ; Ling-Yin Chang [Taïwan] ; Jen-Chi Hsu [Taïwan] ; Clarence J. Peters [États-Unis] ; Andrew H.-J. Wang [Taïwan] ; Ming-Chu Hsu [Taïwan] | Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor |
| 000425 |
Yue-Qing Li [République populaire de Chine] ; Ze-Lin Li [République populaire de Chine] ; Wei-Jie Zhao [République populaire de Chine] ; Rui-Xing Wen [République populaire de Chine] ; Qing-Wei Meng [République populaire de Chine] ; YI ZENG [République populaire de Chine] | Synthesis of stilbene derivatives with inhibition of SARS coronavirus replication |
| 000427 |
XINGNAN LI [États-Unis] ; Robert Vince [États-Unis] | Synthesis and biological evaluation of purine derivatives incorporating metal chelating ligands as HIV integrase inhibitors |
| 000430 |
I-Lin Lu [Taïwan] ; Neeraj Mahindroo [Taïwan] ; Po-Huang Liang [Taïwan] ; Yi-Hui Peng [Taïwan] ; Chih-Jung Kuo [Taïwan] ; Keng-Chang Tsai [Taïwan] ; Hsing-Pang Hsieh [Taïwan] ; Yu-Sheng Chao [Taïwan] ; Su-Ying Wu [Taïwan] | Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease |
| 000439 |
LUHUA LAI [République populaire de Chine] ; XIAOFENG HAN [République populaire de Chine] ; HAO CHEN [République populaire de Chine] ; PING WEI [République populaire de Chine] ; CHANGKANG HUANG [République populaire de Chine] ; SHIYONG LIU [République populaire de Chine] ; KEQIANG FAN [République populaire de Chine] ; LU ZHOU [République populaire de Chine] ; ZHENMING LIU [République populaire de Chine] ; JIANFENG PEI [République populaire de Chine] ; YING LIU [République populaire de Chine] | Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase : SARS-CoV: A scénario of modern drug design |
| 000448 |
Roberto Di Santo [Italie] ; Roberta Costi [Italie] ; Alessandra Roux [Italie] ; Marino Artico [Italie] ; Antonio Lavecchia [Italie] ; Luciana Marinelli [Italie] ; Ettore Novellino [Italie] ; Lucia Palmisano [Italie] ; Mauro Andreotti [Italie] ; Roberta Amici [Italie] ; Clementina Maria Galluzzo [Italie] ; Lucia Nencioni [Italie] ; Anna Teresa Palamara [Italie] ; Yves Pommier [États-Unis] ; Christophe Marchand [États-Unis] | Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors : Design, synthesis, biological activities, and mechanism of action |
| 000457 |
LU ZHOU [République populaire de Chine] ; YING LIU [République populaire de Chine] ; WEILIN ZHANG [République populaire de Chine] ; PING WEI [République populaire de Chine] ; CHANGKANG HUANG [République populaire de Chine] ; JIANFENG PEI [République populaire de Chine] ; YAXIA YUAN [République populaire de Chine] ; LUHUA LAI [République populaire de Chine] | Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors |
| 000459 |
Jan Balzarini [Belgique] ; Els Keyaerts [Belgique] ; Leen Vijgen [Belgique] ; Herman Egberink [Pays-Bas] ; Erik De Clercq [Belgique] ; Marc Van Ranst [Belgique] ; Svetlana S. Printsevskaya [Russie] ; Eugenia N. Olsufyeva [Russie] ; Svetlana E. Solovieva [Russie] ; Maria N. Preobrazhenskaya [Russie] | Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics |
| 000466 |
HUI LI [États-Unis] ; John Tatlock [États-Unis] ; Angelica Linton [États-Unis] ; Javier Gonzalez [États-Unis] ; Allen Borchardt [États-Unis] ; Peter Dragovich [États-Unis] ; Tanya Jewell [États-Unis] ; Tom Prins [États-Unis] ; RU ZHOU [États-Unis] ; Julie Blazel [États-Unis] ; Hans Parge [États-Unis] ; Robert Love [États-Unis] ; Michael Hickey [États-Unis] ; Chau Doan [États-Unis] ; Stephanie Shi [États-Unis] ; Rohit Duggal [États-Unis] ; Cristina Lewis [États-Unis] ; Shella Fuhrman [États-Unis] | Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors |
| 000475 |
Andrea J. Dooley [États-Unis] ; Nice Shindo [États-Unis] ; Barbara Taggart [États-Unis] ; Jewn-Giew Park [États-Unis] ; Yuan-Ping Pang [États-Unis] | From genome to drug lead : Identification of a small-molecule inhibitor of the SARS virus |
| 000485 |
Rakesh Kumar [Canada] ; Wassila Semaine [Canada] ; Monika Johar [Canada] ; D. Lome J. Tyrrell [Canada] ; Babita Agrawal [Canada] | Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication |
| 000489 |
Keng-Chang Tsai [Taïwan] ; Shih-Yuan Chen [Taïwan] ; Po-Huang Liang [Taïwan] ; I-Lin Lu [Taïwan] ; Neeraj Mahindroo [Taïwan] ; Hsing-Pang Hsieh [Taïwan] ; Yu-Sheng Chao [Taïwan] ; Lincoln Liu [Taïwan] ; Donald Liu [Taïwan] ; Wei Lien [Taïwan] ; Thy-Hou Lin [Taïwan] ; Su-Ying Wu [Taïwan] | Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies |
| 000491 |
Han-Zhong Zhang [États-Unis] ; HONG ZHANG [États-Unis] ; William Kemnitzer [États-Unis] ; Ben Tseng [États-Unis] ; Jindrich Jr Cinatl [Allemagne] ; Martin Michaelis [Allemagne] ; Hans Wilhelm Doerr [Allemagne] ; SUI XIONG CAI [États-Unis] | Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors |
| 000500 |
PEI HAO [République populaire de Chine] ; MIN CHEN [République populaire de Chine] ; GUOQING ZHANG [République populaire de Chine] ; WEIZHONG HE [République populaire de Chine] ; YIXUE LI [République populaire de Chine] | Bioinformatics research on the SARS coronavirus (SARS_CoV) in China : SARS-CoV: A scénario of modern drug design |
| 000501 |
LILI CHEN [République populaire de Chine] ; JIAN LI [République populaire de Chine] ; CHENG LUO [République populaire de Chine] ; HONG LIU [République populaire de Chine] ; WEIJUN XU [Singapour] ; GANG CHEN [Singapour] ; OI WAH LIEW [Singapour] ; WEILIANG ZHU [République populaire de Chine] ; CHUM MOK PUAH [Singapour] ; XU SHEN [République populaire de Chine] ; HUALIANG JIANG [République populaire de Chine] | Binding interaction of quercetin -3 -β -galactoside and its synthetic derivatives with SARS-CoV 3CLpro : Structure-activity relationship studies reveal salient pharmacophore features |
| 000503 |
Christopher Mcguigan [Royaume-Uni] ; Alshaimaa Hassan-Abdallah [Royaume-Uni] ; Sheila Srinivasan [Royaume-Uni] ; YIKANG WANG [Royaume-Uni] ; Adam Siddiqui [Royaume-Uni] ; Susan M. Daluge [États-Unis] ; Kristjan S. Gudmundsson [États-Unis] ; HUIQIANG ZHOU [États-Unis] ; Ed W. Mclean [États-Unis] ; Jennifer P. Peckham [États-Unis] ; Thimysta C. Burnette [États-Unis] ; Harry Marr [États-Unis] ; Richard Hazen [États-Unis] ; Lynn D. Condreay [États-Unis] ; Lance Johnson [États-Unis] ; Jan Balzarini [Belgique] | Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives |
| 000504 |
Yu-Shan Wu [Taïwan] ; Wen-Hsing Lin [Taïwan] ; John T.-A. Hsu [Taïwan] ; Hsing-Pang Flsieh [Taïwan] | Antiviral drug discovery against SARS-CoV |
| 000559 |
Andreas J. Kesel [Allemagne] | Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS) |
| 000571 |
Caterina Fattorusso [Italie] ; Sandra Gemma [Italie] ; Stefania Butini [Italie] ; Paul Huleatt [Italie] ; Bruno Catalanotti [Italie] ; Marco Persico [Italie] ; Meri De Angelis [Italie] ; Isabella Fiorini [Italie] ; V Ito Nacci [Italie] ; Anna Ramunno [Italie] ; Manuela Rodriquez [Italie] ; Giovanni Greco [Italie] ; Ettore Novellino [Italie] ; Alberto Bergamini [Italie] ; Stefano Marini [Italie] ; Massimo Coletta [Italie] ; Giovanni Maga [Italie] ; Silvio Spadari [Italie] ; Giuseppe Campiani [Italie] | Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity |
| 000581 |
Erika Martina [Allemagne] ; Nikolaus Stiefl [Allemagne] ; Björn Degel [Allemagne] ; Franziska Schulz [Allemagne] ; Alexander Breuning [Allemagne] ; Markus Schiller [Allemagne] ; Radim Vicik [Allemagne] ; Knut Baumann [Allemagne] ; John Ziebuhr [Allemagne] ; Tanja Schirmeister [Allemagne] | Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor |
| 000604 |
John S. Oxford [Royaume-Uni] ; Shobana Balasingam [Royaume-Uni] ; Charlotte Chan [Royaume-Uni] ; Andrew Catchpole [Royaume-Uni] ; Robert Lambkin [Royaume-Uni] | New antiviral drugs, vaccines and classic public health interventions against SARS coronavirus |
| 000620 |
Jason Paragas [États-Unis] ; Lawrence M. Blatt [États-Unis] ; Chris Hartmann [États-Unis] ; John W. Huggins [États-Unis] ; Tim P. Endy [États-Unis] | Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models |
| 000621 |
Masayuki Saijo [Japon] ; Shigeru Morikawa [Japon] ; Shuetsu Fukushi [Japon] ; Tetsuya Mizutani [Japon] ; Hideki Hasegawa [Japon] ; Noriyo Nagata [Japon] ; Naoko Iwata [Japon] ; Ichiro Kurane [Japon] | Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus |
| 000643 |
XUE WU ZHANG [Hong Kong] ; YEE LENG YAP [Hong Kong] ; Ralf M. Altmeyer [Hong Kong] | Generation of predictive pharmacophore model for SARS-coronavirus main proteinase |
| 000663 |
Jiun-Jie Shie [Taïwan] ; Jim-Min Fang [Taïwan] ; Chih-Jung Kuo [Taïwan] ; Tun-Hsun Kuo [Taïwan] ; Po-Huang Liang [Taïwan] ; Hung-Jyun Huang [Taïwan] ; Wen-Bin Yang [Taïwan] ; Chun-Hung Lin [Taïwan] ; Jiun-Ling Chen [Taïwan] ; Yin-Ta Wu [Taïwan] ; Chi-Huey Wong [Taïwan, États-Unis] | Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease |
| 000679 |
Shiro Shigeta [Japon] ; Toshihiro Yamase [Japon] | Current status of anti-SARS agents |
| 000691 |
Yee-Joo Tan [Singapour] ; SENG GEE LIM [Singapour] ; WANJIN HONG [Singapour] | Characterization of viral proteins encoded by the SARS-coronavirus genome |
| 000703 |
Gerold Hoever [Allemagne] ; Lidia Baltina [Russie] ; Martin Michaelis [Allemagne] ; Rimma Kondratenko [Russie] ; Lia Baltina [Russie] ; Genrich A. Tolstikov [Russie] ; Hans W. Doerr [Allemagne] ; Jindrich Jr Cinatl [Allemagne] | Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus |
| 000722 |
Ulrich Kaeppler [Allemagne] ; Nikolaus Stiefl [Allemagne] ; Markus Schiller [Allemagne] ; Radim Vicik [Allemagne] ; Alexander Breuning [Allemagne] ; Werner Schmitz [Allemagne] ; Daniel Rupprecht [Allemagne] ; Carsten Schmuck [Allemagne] ; Knut Baumann [Allemagne] ; John Ziebuhr [Allemagne] ; Tanja Schirmeister [Allemagne] | A new lead for nonpeptidic active-site-directed inhibitors of the severe acute respiratory syndrome coronavirus main protease discovered by a combination of screening and docking methods |
| 000774 |
Jeffrey H. Toney [États-Unis] ; Sonia Navas-Martin ; Susan R. Weiss ; Andreas Koeller | Sabadinine: A potential non-peptide anti-severe acute-respiratory-syndrome agent identified using structure-aided design |
| 000790 |
Mayuko Takeda-Shitaka [Japon] ; Daisuke Takaya [Japon] ; Chieko Chiba [Japon] ; Hirokazu Tanaka [Japon] ; Hideaki Umeyama [Japon] | Protein Structure Prediction in Structure based drug design : Protein structure prediction in medicinal chemistry |
| 000805 |
XUE WU ZHANG [Hong Kong] ; YEE LENG YAP [Hong Kong] | Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs |
| 000823 |
Dale L. Barnard [États-Unis] ; Valerie D. Hubbard [États-Unis] ; Jared Burton [États-Unis] ; Donald F. Smee [États-Unis] ; John D. Morrey [États-Unis] ; Michael J. Otto [États-Unis] ; Robert W. Sidwell [États-Unis] | Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and β-D-N4-hydroxycytidine |
| 000848 |
XUE WU ZHANG [Hong Kong] ; YEE LENG YAP [Hong Kong] | Exploring the binding mechanism of the main proteinase in SARS-associated coronavirus and its implication to anti-SARS drug design |
| 000959 |
Christopher Mcguigan [Royaume-Uni] ; Alison Jukes [Royaume-Uni] ; Sally Blewett [Royaume-Uni] ; Hubert Barucki [Royaume-Uni] ; Jonathan T. Erichsen [Royaume-Uni] ; Graciella Andrei [Belgique] ; Robert Snoeck [Belgique] ; Erik De Clercq [Belgique] ; Jan Balzarini [Belgique] | Halophenyl furanopyrimidines as potent and selective anti-VZV agents |
| 000972 |
Angelo Ranise [Italie] ; Andrea Spallarossa [Italie] ; Silvia Schenone [Italie] ; Olga Bruno [Italie] ; Francesco Bondavalli [Italie] ; Laura Vargiu [Italie] ; Tiziana Marceddu [Italie] ; Massimo Mura [Italie] ; Paolo La Colla [Italie] ; Alessandra Pani [Italie] | Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: A novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives |
| 000986 |
Chad E. Stephens [États-Unis] ; Takita M. Felder [États-Unis] ; J. Walter Sr Sowell [États-Unis] ; Graciela Andrei [Belgique] ; Jan Balzarini [Belgique] ; Robert Snoeck [Belgique] ; Erik De Clercq [Belgique] | Synthesis and antiviral/antitumor evaluation of 2-amino- and 2-carboxamido-3-arylsulfonylthiophenes and related compounds as a new class of diarylsulfones |
| 000987 |
Anja Johansson [Suède] ; Ina Hubatsch [Suède] ; Eva Akerblom [Suède] ; Gunnar Lindeberg [Suède] ; Susanne Winiwarter [Suède] ; U. Helena Danielson [Suède] ; Anders Hallberg [Suède] | Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain |
| 000988 |
DONG JIN HWANG [Corée du Sud] ; SUN NAM KIM [Corée du Sud] ; JUNG HOON CHOI [Corée du Sud] ; YONG SUP LEE [Corée du Sud] | Dicaffeoyl- or digalloyl pyrrolidine and furan derivatives as HIV integrase inhibitors |
| 000989 |
F. Zouhiri [France] ; J.-F. Mouscadet [France] ; K. Mekouar [France] ; D. Desmaële [France] ; D. Savoure [France] ; H. Leh [France] ; F. Subra [France] ; M. Le Bret [France] ; C. Auclair [France] ; J. D'Angelo [France] | Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture |
| 000990 |
M. Artico [Italie] ; R. Di Santo [Italie] ; R. Costi [Italie] ; E. Novellino [Italie] ; G. Greco [Italie] ; S. Massa [Italie] ; E. Tramontano [Italie] ; M. E. Marongiu [Italie] ; A. De Montis [Italie] ; P. La Colla [Italie] | Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase : Synthesis, biological evaluation, and molecular modeling |
| 000991 |
T. A. Kelly [États-Unis] ; J. R. Proudfoot ; D. W. Mcneil ; U. R. Patel ; E. David ; K. D. Hargrave ; P. M. Grob ; M. Cardozo ; A. Agarwal ; J. Adams | Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. V: 4-Substituted and 2,4-disubstituted analogs of nevirapine |
